Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ABVC BIOPHARMA, INC. issued an aggregate of 1,500,250 shares of the Company’s common stock of common stock to accredited investors and Non-U.S. Persons for aggregate amount of $2,275,468.
- Security
- common stock
- Shares
- an aggregate of 1,500,250 shares of the Company’s common stock
- Purchaser
- accredited investors and Non-U.S. Persons
- Consideration
- aggregate amount of $2,275,468
Exact text from the filing
the Company’s chairman for the maximum time permitted by law. Between May 26, 2025, and January 6, 2026, the Company accepted additional subscriptions in the aggregate amount of $2,275,468 on the same terms and conditions as the Reg S Offering (the “ Additional Subscriptions ”); the Company’s Board of Directors approved the Additional Subscriptions on January 12,
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ABVC BIOPHARMA, INC. issued an aggregate of 1,987,557 shares of common stock to 43 Non-U.S. Persons for aggregate gross proceeds of approximately $1,289,750.
- Security
- common stock
- Shares
- an aggregate of 1,987,557 shares
- Purchaser
- 43 Non-U.S. Persons
- Consideration
- aggregate gross proceeds of approximately $1,289,750
Exact text from the filing
the Company sold an aggregate of 1,987,557 shares (the “ Shares ”) of its Common Stock to 43 Non-U.S. Persons (as defined in Regulation S under the Securities Act). The offer and sale of the Shares was exempt from the registration provisions of the Securities Act, pursuant to Regulation S thereunder (“ Regulation S ”); the Company received aggregate gross proceeds of approximately $1,289,750 for the Shares
View on SEC.gov